The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Can A+AVD replace PET-directed strategies for the frontline treatment of Hodgkin lymphoma?
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, discusses a debate on whether a combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine chemotherapy (A+AVD) should replace PET-directed therapy for the frontline treatment of Hodgkin Lymphoma (HL). PET-directed strategies are beneficial when using intensive chemotherapy to reduce the risk of long-term toxicities. Prof. Ansell explains that novel combinations such as A+AVD are less toxic, allowing them to be utilized for a longer period of time and improve patient outcomes without the need for PET-directed strategies. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
